MCID: CVD001
MIFTS: 58

Covid-19

Categories: Infectious diseases

Aliases & Classifications for Covid-19

MalaCards integrated aliases for Covid-19:

Name: Covid-19 12 29 42 44 15
Wuhan Seafood Market Pneumonia Virus Infection 12
Wuhan Coronavirus Infection 12
2019 Novel Coronavirus 12
Sars-Cov-2 Infection 12
2019-Ncov Infection 12
Covid19 12

Classifications:



External Ids:

Disease Ontology 12 DOID:0080600
MeSH 44 D000086382
SNOMED-CT 67 840539006
ICD10 32 U07.1
UMLS 70 C5203670

Summaries for Covid-19

MedlinePlus : 42 COVID-19 (coronavirus disease 2019) is an illness caused by a virus. This virus is a new coronavirus that has spread throughout the world. It is thought to spread mainly through close contact from person to person. On this page, you'll find links to resources on important issues such as symptoms, risks, and how you can protect yourself and your family. We also have pages on COVID-19 testing and vaccines, including the vaccines that have been authorized in the United States and the others that are still in progress.

MalaCards based summary : Covid-19, also known as wuhan seafood market pneumonia virus infection, is related to adult respiratory distress syndrome and disease by infectious agent. An important gene associated with Covid-19 is ACE2 (Angiotensin Converting Enzyme 2), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Sofosbuvir and Ledipasvir have been mentioned in the context of this disorder. Affiliated tissues include kidney, endothelial and breast, and related phenotypes are cardiovascular system and hematopoietic system

Disease Ontology : 12 A Coronavirus infection that is characterized by fever, cough and shortness of breath and that has material basis in SARS-CoV-2.

Wikipedia : 73 2020... more...

Related Diseases for Covid-19

Diseases related to Covid-19 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1963)
# Related Disease Score Top Affiliating Genes
1 adult respiratory distress syndrome 32.2 IL6 IL1B IFNA2 CXCL8 ACE
2 disease by infectious agent 32.2 TLR4 IL6 IL4 IL1B IFNB1
3 middle east respiratory syndrome 32.1 TMPRSS2 IFNB1 DPP4 CXCL10 ACE2
4 pulmonary embolism 32.0 TNNI3 NPPB F3 ACE
5 pneumonia 31.9 TLR4 IL6 IL4 IL1B CXCL8 CXCL10
6 severe acute respiratory syndrome 31.9 TMPRSS2 TLR4 IL6 IL1B IFNB1 CXCL8
7 cardiogenic shock 31.7 NPPB IL6
8 stroke, ischemic 31.7 TLR4 NPPB IL6 IL1B F3 ACE
9 influenza 31.7 TMPRSS2 IL6 IL1B IFNB1 CXCL10
10 viral pneumonia 31.6 IL6 IFNB1 CXCL8 CXCL10 ACE2
11 cerebrovascular disease 31.6 TLR4 NPPB IL6 ACE
12 congestive heart failure 31.6 TNNI3 NPPB IL6 IL1B ACE
13 respiratory failure 31.6 TLR4 NPPB IL6 IL1B F3 CXCL8
14 kawasaki disease 31.5 NPPB IL6 IL4 IL1B CCL2
15 mycobacterium tuberculosis 1 31.5 TLR4 IL4 IFNB1 CXCL10
16 neutropenia 31.4 IL6 IL1B IFNA2 CXCL8
17 encephalitis 31.4 IL6 IL1B IFNB1 CXCL10 CCL2
18 bacterial pneumonia 31.4 TLR4 IL6 IL1B CXCL8
19 purpura 31.4 IL6 IL4 F3 ACE
20 plague 31.4 TLR4 IL6 IL1B
21 conjunctivitis 31.4 TLR4 IL6 IL4 CXCL8 CCL2
22 sleep disorder 31.3 IL6 IL1B CXCL8 ACE
23 acute myocarditis 31.3 TNNI3 NPPB ACE
24 myocarditis 31.3 TNNI3 TLR4 NPPB IL6 IL4 IL1B
25 mental depression 31.3 IL6 IL1B DPP4
26 myelitis 31.3 IL6 IFNB1 CXCL8
27 appendicitis 31.3 TLR4 IL6 IL1B CXCL8 CCL2
28 hemopericardium 31.3 TNNI3 F3
29 limb ischemia 31.3 TNNI3 IL6 CCL2 ACE
30 dermatitis 31.3 IL6 IL4 IL1B CXCL8
31 exanthem 31.3 IL6 IL1B F3 EGFR CXCL8 ACE
32 urticaria 31.3 IL6 IL4 CXCL8 ACE
33 acute pancreatitis 31.3 TLR4 IL6 IL1B CXCL8
34 measles 31.3 TLR4 IL6 IL2RA IL1B IFNB1
35 chickenpox 31.3 IL6 IL4 IFNB1
36 pericardial effusion 31.3 TNNI3 NPPB IL6 F3 ACE
37 common cold 31.2 IL6 IL4 IL1B IFNA2 CXCL8 ACE2
38 liver disease 31.2 IL6 IL1B IFNA2 F3 CXCL8
39 orchitis 31.2 IL6 IL1B ACE2
40 erythema multiforme 31.2 IL6 IL4 CXCL8
41 acute myocardial infarction 31.2 TNNI3 NPPB IL6 F3 ACE
42 body mass index quantitative trait locus 11 31.2 TLR4 IL6 IL4 IL1B DPP4 CXCL8
43 atrioventricular block 31.1 TNNI3 NPPB ACE
44 chronic kidney disease 31.1 TNNI3 TLR4 NPPB IL6 IL1B F3
45 urinary tract infection 31.1 TLR4 ACE
46 acne 31.1 IL6 IL1B IFNA2 CXCL8
47 end stage renal disease 31.1 NPPB IL6 IL1B CCL2 ACE
48 cardiac tamponade 31.1 TNNI3 NPPB F3 ACE
49 pulmonary edema 31.1 TNNI3 NPPB IL1B CXCL8 ACE
50 endocarditis 31.1 TNNI3 IL6 CXCL8

Graphical network of the top 20 diseases related to Covid-19:



Diseases related to Covid-19

Symptoms & Phenotypes for Covid-19

MGI Mouse Phenotypes related to Covid-19:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.29 ACE ACE2 ADAM17 CXCL10 DPP4 EGFR
2 hematopoietic system MP:0005397 10.28 ACE ACE2 ADAM17 CXCL10 DPP4 EGFR
3 growth/size/body region MP:0005378 10.27 ACE ACE2 ADAM17 DPP4 EGFR F3
4 immune system MP:0005387 10.27 ACE ACE2 ADAM17 CCL2 CXCL10 DPP4
5 homeostasis/metabolism MP:0005376 10.25 ACE ACE2 ADAM17 CXCL10 DPP4 EGFR
6 mortality/aging MP:0010768 10.2 ACE ACE2 ADAM17 CXCL10 DPP4 EGFR
7 muscle MP:0005369 9.86 ACE2 ADAM17 EGFR F3 IL6 NRP1
8 neoplasm MP:0002006 9.81 ACE EGFR F3 IFNB1 IL1B IL6
9 respiratory system MP:0005388 9.7 ACE2 ADAM17 DPP4 EGFR F3 IL2RA
10 vision/eye MP:0005391 9.32 ACE ACE2 ADAM17 EGFR F3 IL2RA

Drugs & Therapeutics for Covid-19

Drugs for Covid-19 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 865)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Sofosbuvir Approved Phase 4 1190307-88-0 45375808
2
Ledipasvir Approved Phase 4 1256388-51-8 67505836
3 Bentonite Approved Phase 4
4
Ivermectin Approved, Investigational, Vet_approved Phase 4 70288-86-7 6474909
5
Clarithromycin Approved Phase 4 81103-11-9 84029
6
BCG vaccine Approved, Investigational Phase 4
7
Ibuprofen Approved Phase 4 15687-27-1 3672
8
Protein C Approved Phase 4
9
Apixaban Approved Phase 4 503612-47-3 10182969
10
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
11
Apremilast Approved, Investigational Phase 4 608141-41-9 11561674
12
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
13
Tazobactam Approved Phase 4 89786-04-9 123630
14
Piperacillin Approved Phase 4 66258-76-2 43672
15
Clopidogrel Approved Phase 4 113665-84-2, 120202-66-6 60606
16
Ticagrelor Approved Phase 4 274693-27-5 9871419
17
Ofloxacin Approved Phase 4 82419-36-1 4583
18
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
19
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
20
Fondaparinux Approved, Investigational Phase 4 104993-28-4
21
Ceftaroline fosamil Approved, Investigational Phase 4 229016-73-3
22
Roxithromycin Approved, Investigational, Withdrawn Phase 4 80214-83-1 6915744 444037
23
Moxifloxacin Approved, Investigational Phase 4 354812-41-2, 151096-09-2 152946
24
Cefditoren Approved, Investigational Phase 4 117467-28-4, 104145-95-1 9870843 9571074
25
Argatroban Approved, Investigational Phase 4 74863-84-6 152951
26
Bivalirudin Approved, Investigational Phase 4 128270-60-0 16129704
27
Nintedanib Approved Phase 4 656247-17-5 56843413
28
Zinc sulfate Approved, Investigational Phase 4 7733-02-0
29
Amlodipine Approved Phase 4 88150-42-9 2162
30
Bismuth subsalicylate Approved, Vet_approved Phase 4 14882-18-9 53629521
31
Loperamide Approved Phase 4 53179-11-6 3955
32
Rivaroxaban Approved Phase 4 366789-02-8
33
Tenecteplase Approved Phase 4 191588-94-0
34
Interferon beta-1a Approved, Investigational Phase 4 145258-61-3 6438354
35
Iron Approved Phase 4 7439-89-6 23925 29936
36
Povidone-iodine Approved Phase 4 25655-41-8
37
Isotretinoin Approved Phase 4 4759-48-2 5282379 5538
38
Coal tar Approved Phase 4 8007-45-2
39
Povidone Approved Phase 4 9003-39-8 131751496
40
Iodine Approved, Investigational Phase 4 7553-56-2 807
41
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
42
Histamine Approved, Investigational Phase 4 51-45-6, 75614-87-8 774
43
Famotidine Approved Phase 4 76824-35-6 3325
44
Nicotinamide Approved, Investigational Phase 4 98-92-0 936
45
Testosterone Approved, Investigational Phase 4 58-22-0 6013
46
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
47
Hydrogen peroxide Approved, Vet_approved Phase 4 7722-84-1 784
48
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
49
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
50
Valproic acid Approved, Investigational Phase 4 99-66-1 3121

Interventional clinical trials:

(show top 50) (show all 4892)
# Name Status NCT ID Phase Drugs
1 Prevention of Infection and Incidence of COVID-19 in Medical Personnel Assisting Patients With New Coronavirus Disease: a Randomised Controlled Trial Completed NCT04405999 Phase 4 Bromhexine Hydrochloride
2 An Open Clinical Trial to Evaluate Ganovo(Danoprevir ) Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection Completed NCT04291729 Phase 4 Ganovo+ritonavir+/-Interferon nebulization
3 An Open Clinical Trial to Evaluate Danoprevir Sodium Tablets Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection Completed NCT04345276 Phase 4 Danoprevir+Ritonavir
4 TOCILIZUMAB - An Option for Patients With COVID-19 Associated Cytokine Release Syndrome; A Single Center Experience Completed NCT04730323 Phase 4 Tocilizumab
5 Efficacy of Adding Sofosbuvir/Ledipasvir Combination, or Nitazoxanide to the Standard of Care in Treatment of COVID-19: A Randomized Controlled Trial Completed NCT04498936 Phase 4 Sofosbuvir and Ledipasvir;Nitazoxanide
6 Rapid Development and Implementation of a Remote ECG-monitored Prospective Randomized Clinical Trial During a Pandemic: Hydroxychloroquine Prophylaxis in COVID-19 Household Contacts Completed NCT04652648 Phase 4 Hydroxychloroquine
7 Effectiveness of Ivermectin in SARS-CoV-2/COVID-19 Patients Completed NCT04739410 Phase 4 Ivermectin
8 Ivermectin Role in Severe Covid-19 Treatment; a Double-blinded, Randomized Clinical Trial Completed NCT04746365 Phase 4 ivermectin;hydroxychloroquine;Placebo
9 A Randomized, Open-label, Multicentre, Comparative Study of Therapeutic Efficacy, Safety, and Tolerability of BNO 1030 Extract, in the Treatment of Mild Forms of COVID-19 Completed NCT04797936 Phase 4 BNO 1030
10 Multicenter, Randomized, Open-label, Non-commercial, Investigator-initiated Study to Evaluate the Efficacy and Safety of Chloroquine Phosphate in Combination With Telemedicine Care in the Risk Reduction of COVID-19 Related Hospitalization or Death, in Ambulatory Patients With COVID-19 Being at Risk of Serious Complications Completed NCT04331600 Phase 4 Chloroquine phosphate
11 Therapeutic Plasma Exchange for COVID-19-associated Hyperviscosity Completed NCT04441996 Phase 4
12 Telmisartan for Treatment of COVID-19 Patients: an Open Label Randomized Trial Completed NCT04355936 Phase 4 Telmisartan arm will receive 80 mg Telmisartan twice daily plus standard care.
13 A Randomized Study Evaluating the Safety and Efficacy of Hydroxychloroquine and Zinc in Combination With Either Azithromycin or Doxycycline for the Treatment of COVID-19 in the Outpatient Setting Completed NCT04370782 Phase 4 Hydroxychloroquine;Azithromycin;Zinc Sulfate;Doxycycline
14 A Prospective, Randomized, Open-label, Interventional Study to Investigate the Efficacy of Sargramostim (Leukine®) in Improving Oxygenation and Short- and Long-term Outcome of COVID-19 (Corona Virus Disease) Patients With Acute Hypoxic Respiratory Failure. Completed NCT04326920 Phase 4 Sargramostim
15 Efficacy of Fuzheng Huayu Tablets for Treating Pulmonary Inflammation in Patients With COVID-19: A Case-Control Study Completed NCT04645407 Phase 4 Fuzheng Huayu tablet
16 Prevention of Coronavirus Disease (COVID-19) Outbreaks by Prophylactic Treatment With Nitazoxanide Completed NCT04406246 Phase 4 Nitazoxanide 500Mg Oral Tablet
17 Stopping ACE-inhibitors in COVID-19: A Randomized Controlled Trial Completed NCT04353596 Phase 4 ACE inhibitor, angiotensin receptor blocker
18 A Randomized, Placebo-Controlled Study Evaluating the Efficacy of Zinc for the Treatment of COVID-19 in the Outpatient Setting Completed NCT04621461 Phase 4 Placebo
19 The Effect of Berberine on Intestinal Function and Inflammatory Mediators in Severe Patients With Covid-19 Completed NCT04479202 Phase 4 Berberine;Montmorrillonite
20 Evaluation of Sofosbuvir and Daclatasvir Combo in COIVD-19 Patients in Egypt (Single Center Study) Completed NCT04773756 Phase 4 Sofosbuvir 400 MG/ Daclatasvir 60mg
21 The Effectiveness of Cerebrolycin for Treatment of Post-covid Olfactory and Gustatory Dysfunctions: A Pilot Study Completed NCT04830943 Phase 4 Cerebrolysin
22 Comparative Therapeutic Efficacy and Safety of Remdesivir Plus Lopinavir/ Ritonavir and Tocilizumab Versus Hydroxychloroquine Plus Ivermectin and Tocilizumab in COVID-19 Patients. Recruiting NCT04779047 Phase 4 Remdesivir;Hydroxychloroquine;Tocilizumab;Lopinavir/ Ritonavir;Ivermectin
23 A Randomized Clinical Trial for Enhanced Trained Immune Responses Through Bacillus Calmette-Guérin Vaccination to Prevent Infections by COVID-19: The ACTIVATE II Trial Recruiting NCT04414267 Phase 4
24 Pilot Study of Safety and Efficacy of Nitazoxanide in Post-exposure Prophylaxis in Household Contacts of Patients With Confirmed SARS-CoV-2 Infection Recruiting NCT04788407 Phase 4 Nitazoxanide;Placebo
25 The Study of Quadruple Therapy Zinc, Quercetin, Bromelain and Vitamin C on the Clinical Outcomes of Patients Infected With COVID-19 Recruiting NCT04468139 Phase 4 Quercetin;Zinc;Vitamin C
26 Impact of Colchicine on the Clinical Outcome of COVID-19 and the Development of Post-COVID-19 Pulmonary Fibrosis: Randomized Controlled Clinical Trial Recruiting NCT04818489 Phase 4 Colchicine 0.5 MG
27 A Randomized, Double Blind, Placebo Controlled, Cross-Over, Proof-of-Concept Study to Evaluate the Benefit of RUCONEST (C1 Esterase Inhibitor [Recombinant]) in Improving Neurological Symptoms in Post-SARS-CoV-2 Infection Recruiting NCT04705831 Phase 4 Ruconest
28 Randomized Open Label Study of Standard of Care Plus an Angiotensin II Receptor Blocker Compared to Standard of Care Alone to Minimize the Progression to Respiratory Failure in SARS-CoV-2 Infection Recruiting NCT04340557 Phase 4 Losartan
29 A Randomized Double-blinded Placebo-controlled Outpatient Clinical Trial in High Risk Population Confirmed COVID-19 Patients Using Ivermectin and Doxycycline to Prevent COVID-19 Illness-related Hospitalization (COVIVER-OUT PLUS) Recruiting NCT04729140 Phase 4 Ivermectin Tablets;Doxycycline Tablets;Placebo
30 Efficacy of a Nasal Spray Containing Iota-Carrageenan in the Prophylaxis of COVID-19 Disease in Health Personnel Dedicated to Patients Care With COVID-19. Multicenter, Randomized, Double-blind, Placebo-controlled Trial (CARR-COV-02) Recruiting NCT04521322 Phase 4 Iota-Carrageenan
31 Fluoxetine to Reduce Intubation and Death After COVID19 Infection Recruiting NCT04377308 Phase 4 Fluoxetine
32 mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Repurposed Drugs (TACTIC-R) Recruiting NCT04390464 Phase 4 Ravulizumab;Baricitinib
33 Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY Disease Recruiting NCT04394117 Phase 4 Angiotensin Receptor Blockers
34 Immunological Responses After Vaccination for COVID-19 With the Messenger Ribonucleic Acid (mRNA) Vaccine Comirnaty in Immunosuppressed and Immunocompetent Individuals. An Open and Non-randomized, Phase IV Multicenter Study Recruiting NCT04780659 Phase 4
35 Open, Controlled, Randomized Clinical Trial to Evaluate the Efficacy and Safety of Cyclosporine Plus Standard Treatment vs Standard Treatment Only in Hospitalized Patients With COVID-19 Infection Recruiting NCT04392531 Phase 4 Cyclosporine;Standard treatment
36 Phase IV Study to Evaluate the Effectiveness of the Inactivated Adsorbed Vaccine Against COVID-19 CoronaVac, Among Public Safety and Education Workers With Risk Factors for Severity, in Manaus (Amazonas) Recruiting NCT04789356 Phase 4
37 COVID-19 Primary Care Platform for Early Treatment and Recovery (COPPER) Study: an Open-label Randomized Controlled Trial Recruiting NCT04746430 Phase 4 Dexamethasone
38 Apixaban for PrOphyLaxis of thromboemboLic Outcomes in COVID-19 - the Apollo Trial Recruiting NCT04746339 Phase 4 Apixaban 2.5 MG;Placebo
39 Comparative Therapeutic Efficacy and Safety of Remdesivir Versus Lopinavir/ Ritonavir and Remdesivir Combination in COVID-19 Patients Recruiting NCT04738045 Phase 4 Remdesivir;Lopinavir/ Ritonavir and Remdesivir combination
40 Effects of Higher Dose and Lower Dose of Dexamethasone for Hospitalized Patients With COVID-19 Recruiting NCT04707534 Phase 4 Dexamethasone
41 BCG Vaccine to Reduce Unplanned Absenteeism Due to Illness of Health Care Workers During the COVID-19 Pandemic. A Multi-center Randomised Controlled Trial (BCG-COVID-RCT) Recruiting NCT04641858 Phase 4
42 Efficacy of Low or High Dose of Dexamethasone in Patients With Respiratory Failure by COVID-19 Recruiting NCT04726098 Phase 4 Dexamethasone high dose;Dexamethasone low dose
43 Effect of Dexamethasone in Patients With ARDS and COVID-19 - Prospective, Multi-centre, Open-label, Parallel-group, Randomized Controlled Trial (REMED Trial) Recruiting NCT04663555 Phase 4 Dexamethasone
44 Vitamin D Supplementation and Covid-19: a Randomised, Double- Blind, Controlled Study Recruiting NCT04636086 Phase 4 Cholecalciferol
45 The Use of Tocilizumab in the Management of Patients Who Have Severe COVID-19 With Suspected Pulmonary Hyperinflammation Recruiting NCT04377750 Phase 4 Tocilizumab
46 Anosmia and / or Ageusia in COVID-19: Timeline, Treatment With Early Corticosteroid and Recovery Recruiting NCT04528329 Phase 4 Early-Dexamethasone;Late dexamethazone
47 A Multicenter, Adaptive, Randomized Controlled Platform Trial of the Safety and Efficacy of Antithrombotic Strategies in Hospitalized Adults With COVID-19 Recruiting NCT04505774 Phase 4 theraputic heparin;prophylactic heparin;P2Y12
48 Does Silymarin Mitigate Clinical Course of COVID-19 in Patients Admitted to an Internal Medicine Ward With Elevated Liver Enzymes? Recruiting NCT04816682 Phase 4 Silymarin
49 Timing of Corticosteroids in COVID-19 Recruiting NCT04530409 Phase 4 Early-Dexamethasone;Late-Dexamethasone
50 Efficacy of Palmitoylethanolamide, in add-on to Standard Therapy, on Inflammatory Markers of Patients With Interstitial Pneumonia Due to COVID-19. A Pilot Controlled, Randomized, Open Lable Clinical Study Recruiting NCT04568876 Phase 4

Search NIH Clinical Center for Covid-19

Cochrane evidence based reviews: covid-19

Genetic Tests for Covid-19

Genetic tests related to Covid-19:

# Genetic test Affiliating Genes
1 Covid-19 29

Anatomical Context for Covid-19

MalaCards organs/tissues related to Covid-19:

40
Kidney, Endothelial, Breast, Skin, Liver, Neutrophil, Eye

Publications for Covid-19

Articles related to Covid-19:

(show top 50) (show all 30000)
# Title Authors PMID Year
1
Efficacy and safety of Levamisole treatment in clinical presentations of non-hospitalized patients with COVID-19: a double-blind, randomized, controlled trial. 42 61
33761870 2021
2
Effectiveness and safety review of Chinese herbal sachets for external use in the treatment of COVID-19 pandemic: A protocol for systematic review and meta-analysis. 61 42
33761686 2021
3
African Americans Struggle With the Current COVID-19. 42 61
33759842 2020
4
ECONOMIC CRISES AS A MOTIVE FOR CHANGE IN HEALTH CARE SYSTEMS - A HISTORICAL PERSPECTIVE WITH REFERENCE TO THE COVID-19 PANDEMIC. 61
33535767 2021
5
Health-care guidelines and policies during the COVID-19 pandemic in Mexico: A case of health-inequalities. 61
33521627 2021
6
Epidemiological investigation of a COVID-19 family cluster outbreak transmitted by a 3-month-old infant. 61
33489103 2021
7
Protecting women: new domestic violence countermeasures for COVID-19 in Japan. 61
33533321 2021
8
CPMPARISON between COVID-19 and MERS demographic data in Saudi Arabia: a retrospective study. 61
33797350 2021
9
Offline: The lessons of smallpox eradication for COVID-19. 61
33341128 2021
10
Remote clinical training practice in the neurology internship during the COVID-19 pandemic. 61
33685381 2021
11
External validation of a clinical risk score to predict hospital admission and in-hospital mortality in COVID-19 patients. 61
32997542 2021
12
Disparities in case frequency and mortality of coronavirus disease 2019 (COVID-19) among various states in the United States. 61
33138653 2021
13
Post COVID 19 multisystem inflammatory syndrome in an older adult. 61
33719897 2021
14
Immune dysregulation and system pathology in COVID-19. 61
33757410 2021
15
A novel DNA and protein combination COVID-19 vaccine formulation provides full protection against SARS-CoV-2 in rhesus macaques. 61
33555988 2021
16
Relation between insulin growth factor 1 and survival after SARS-CoV-2(COVID 19) infection in elderly kidney transplant recipients. 61
33627041 2021
17
COVID-19 evolution during the pandemic - Implications of new SARS-CoV-2 variants on disease control and public health policies. 61
33494661 2021
18
Lessons learned 1 year after SARS-CoV-2 emergence leading to COVID-19 pandemic. 61
33666147 2021
19
IL-6 and other biomarkers as predictors of severity in COVID-19. 61
33305624 2021
20
Effect of a genetically engineered interferon-alpha versus traditional interferon-alpha in the treatment of moderate-to-severe COVID-19: a randomised clinical trial. 61
33620016 2021
21
Classification of COVID-19 pneumonia from chest CT images based on reconstructed super-resolution images and VGG neural network. 61
33643612 2021
22
Virus-associated ribozymes and nano carriers against COVID-19. 61
33645342 2021
23
Admission hyperglycaemia as a predictor of mortality in patients hospitalized with COVID-19 regardless of diabetes status: data from the Spanish SEMI-COVID-19 Registry. 61
33063540 2021
24
Efficacy of the current investigational drugs for the treatment of COVID-19: a scoping review. 61
33706639 2021
25
Time-course analysis reveals that corticosteroids resuscitate diminished CD8+ T cells in COVID-19: a retrospective cohort study. 61
33183091 2021
26
Performance of prediction models for short-term outcome in COVID-19 patients in the emergency department: a retrospective study. 61
33629918 2021
27
Clinical features and outcome of maintenance hemodialysis patients with COVID-19 from a tertiary nephrology care center in Romania. 61
33307933 2021
28
Association between an increase in blood urea nitrogen at 24 h and worse outcomes in COVID-19 pneumonia. 61
33583325 2021
29
Transmission rates and environmental reservoirs for COVID-19 - a modeling study. 61
33402047 2021
30
Clinical outcomes of initially asymptomatic patients with COVID-19: a Korean nationwide cohort study. 61
33583290 2021
31
Evaluation of a comprehensive pre-procedural screening protocol for COVID-19 in times of a high SARS CoV-2 prevalence: a prospective cross-sectional study. 61
33583292 2021
32
Psychological problems in general population during covid-19 pandemic in Pakistan: role of cognitive emotion regulation. 61
33307858 2021
33
Spontaneous ilio-psoas haematomas (IPHs): a warning for COVID-19 inpatients. 61
33491498 2021
34
Chest CT features associated with the clinical characteristics of patients with COVID-19 pneumonia. 61
33426973 2021
35
COVID-19 pandemic: a catalyst for transformation of a summer online research program. 61
33567998 2021
36
Conducting multiple mini-interviews in the midst of COVID-19 pandemic. 61
33618631 2021
37
The perceptions of anatomy teachers for different majors during the COVID-19 pandemic: a national Chinese survey. 61
33720807 2021
38
Heterologous prime-boost: breaking the protective immune response bottleneck of COVID-19 vaccine candidates. 61
33691606 2021
39
Cross-reactive antibody against human coronavirus OC43 spike protein correlates with disease severity in COVID-19 patients: a retrospective study. 61
33734013 2021
40
Human challenge trials to assess the efficacy of currently approved COVID-19 vaccines against SARS-CoV-2 variants. 61
33635184 2021
41
Age and frailty in COVID-19 vaccine development. 61
33220853 2021
42
COVID-19-associated cytokine storm syndrome and diagnostic principles: an old and new Issue. 61
33522893 2021
43
COVID-19: anxiety among hospital staff and associated factors. 61
33350869 2021
44
Hematologic autoimmune disorders in the course of COVID-19: a systematic review of reported cases. 61
33594951 2021
45
Evaluation of the susceptibility and fatality of lung cancer patients towards the COVID-19 infection: A systemic approach through analyzing the ACE2, CXCL10 and their co-expressed genes. 61
33585826 2021
46
Increased expression of hypoxia-induced factor 1α mRNA and its related genes in myeloid blood cells from critically ill COVID-19 patients. 61
33345622 2021
47
Can povidone iodine gargle/mouthrinse inactivate SARS-CoV-2 and decrease the risk of nosocomial and community transmission during the COVID-19 pandemic? An evidence-based update. 61
33747261 2021
48
Risk factors of developing critical conditions in Iranian patients with COVID-19. 61
33521624 2021
49
A skeleton in the closet: The implications of COVID-19 on XDR strain of typhoid in Pakistan. 61
33521736 2021
50
The effects of the COVID-19 pandemic on food losses in the agricultural value chains in Africa: The Nigerian case study. 61
33564750 2021

Variations for Covid-19

Expression for Covid-19

Search GEO for disease gene expression data for Covid-19.

Pathways for Covid-19

Pathways related to Covid-19 according to GeneCards Suite gene sharing:

(show top 50) (show all 69)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.09 TLR4 IL6 IL4 IL2RA IL1B IFNB1
2
Show member pathways
13.88 NRP1 IL6 IL4 IL2RA IL1B EGFR
3
Show member pathways
13.72 TLR4 IL6 IL4 IL2RA IL1B IFNB1
4
Show member pathways
13.69 TMPRSS2 TLR4 NRP1 IL6 IL1B IFNB1
5
Show member pathways
13.6 IL6 IL4 IL2RA IL1B IFNB1 IFNA2
6
Show member pathways
13.46 TLR4 IL6 IL4 IL2RA IL1B EGFR
7
Show member pathways
13.34 NRP1 IL6 IL4 IL2RA IL1B EGFR
8
Show member pathways
13.31 IL6 IL4 IL2RA IL1B IFNB1 IFNA2
9
Show member pathways
13.19 TLR4 IL6 IL1B IFNB1 IFNA2 EGFR
10
Show member pathways
13.11 NRP1 IL6 IL4 IL2RA EGFR CCL2
11
Show member pathways
13.04 TLR4 IL6 IL4 IL2RA IFNB1 IFNA2
12
Show member pathways
12.97 TLR4 IL6 IL1B IFNB1 IFNA2 EGFR
13
Show member pathways
12.91 IL6 IL4 IL2RA IL1B IFNA2 CXCL8
14 12.9 IL6 IL4 IL2RA IFNA2 EGFR CXCL8
15 12.83 IL6 IL1B IFNB1 IFNA2 CCL2
16
Show member pathways
12.71 TLR4 IL6 IL1B IFNB1 IFNA2 F3
17
Show member pathways
12.66 TLR4 IL6 IL4 IL1B EGFR
18
Show member pathways
12.65 TLR4 IL6 IL4 IL2RA IL1B
19 12.63 IL4 IL2RA IL1B CXCL10 CCL2
20
Show member pathways
12.61 IL6 IL1B IFNB1 IFNA2 CXCL10
21
Show member pathways
12.49 IL6 IL4 IL2RA IFNB1 IFNA2 EGFR
22 12.47 TLR4 IL1B IFNB1 EGFR CXCL8
23
Show member pathways
12.4 IL6 IL2RA CXCL8 CXCL10 CCL2
24
Show member pathways
12.4 IL6 IL4 IL1B CXCL8 CXCL10 CCL2
25
Show member pathways
12.37 IL6 IL4 IL1B CCL2
26
Show member pathways
12.36 TMPRSS2 TLR4 IL6 IL2RA IL1B IFNB1
27
Show member pathways
12.31 TLR4 IL6 IFNB1 CXCL8
28 12.3 TLR4 IL6 IL1B IFNB1 IFNA2
29
Show member pathways
12.26 TLR4 IL1B IFNB1 IFNA2
30 12.17 TLR4 IL6 IL1B IFNB1 IFNA2 CXCL8
31 12.12 TLR4 IL6 IL1B IFNB1 CXCL8 CCL2
32
Show member pathways
12.09 TLR4 IL2RA IL1B EGFR
33
Show member pathways
12.08 TLR4 IL6 IL4 IL1B IFNB1 CXCL8
34 12.07 IL6 IL4 IL1B CXCL8 CCL2
35 12.06 IL6 IL4 IL2RA IFNA2
36 12.05 IL6 IL1B IFNB1 CXCL10 CCL2
37
Show member pathways
12.02 NRP1 IL6 IL4 IL2RA IL1B IFNB1
38 12.01 IL6 IL1B IFNB1 CXCL8
39 11.99 TLR4 IL6 IL1B CXCL8
40 11.99 IL6 IL1B F3 CXCL8 CCL2
41 11.97 IL6 IL4 IL2RA IL1B
42
Show member pathways
11.93 TLR4 IL6 IL4 IL1B
43 11.92 TLR4 IL6 IL1B CXCL8 CCL2
44 11.84 TLR4 IL6 IL1B CXCL8
45 11.83 IL6 IL4 CXCL8
46 11.82 IL4 IL2RA IL1B
47 11.8 NRP1 IL6 IL1B IFNB1 IFNA2
48
Show member pathways
11.79 TLR4 IL6 IL1B
49
Show member pathways
11.79 IL4 IL2RA CXCL8
50 11.77 TLR4 IL6 IL4 IL2RA

GO Terms for Covid-19

Cellular components related to Covid-19 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.8 NRP1 NPPB IL6 IL4 IL1B IFNB1
2 cell surface GO:0009986 9.76 TLR4 NRP1 IL2RA F3 EGFR DPP4
3 membrane raft GO:0045121 9.56 EGFR DPP4 ADAM17 ACE2
4 extracellular region GO:0005576 9.53 TMPRSS2 NRP1 NPPB IL6 IL4 IL1B

Biological processes related to Covid-19 according to GeneCards Suite gene sharing:

(show all 38)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.28 TLR4 NRP1 IL6 IL4 IL1B EGFR
2 positive regulation of gene expression GO:0010628 10.04 TLR4 IL6 IL4 IL1B F3 CXCL8
3 positive regulation of cell proliferation GO:0008284 10.02 IL6 IL4 IL1B EGFR DPP4 CXCL10
4 cell-cell signaling GO:0007267 9.97 NRP1 IL1B IFNA2 CXCL10
5 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.95 TLR4 NRP1 EGFR CCL2
6 defense response to virus GO:0051607 9.94 IL6 IFNB1 IFNA2 CXCL10
7 response to lipopolysaccharide GO:0032496 9.92 TLR4 IL1B CXCL10 ADAM17
8 defense response GO:0006952 9.91 IFNB1 IFNA2 CXCL8 CXCL10
9 cellular response to mechanical stimulus GO:0071260 9.85 TLR4 IL1B EGFR
10 neutrophil chemotaxis GO:0030593 9.85 CXCL8 CXCL10 CCL2
11 positive regulation of cell migration GO:0030335 9.85 IL4 IL1B F3 EGFR CXCL10 ADAM17
12 regulation of insulin secretion GO:0050796 9.84 IL6 IL1B DPP4
13 viral entry into host cell GO:0046718 9.84 NRP1 EGFR DPP4 ACE2
14 chemokine-mediated signaling pathway GO:0070098 9.83 CXCL8 CXCL10 CCL2
15 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.83 IL6 IL4 IFNA2
16 B cell differentiation GO:0030183 9.83 IL4 IFNB1 IFNA2 ADAM17
17 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.82 TLR4 IL1B EGFR
18 positive regulation of T cell proliferation GO:0042102 9.81 IL6 IL4 IL2RA IL1B
19 cellular response to lipopolysaccharide GO:0071222 9.8 TLR4 IL6 IL1B CXCL8 CXCL10 CCL2
20 cell surface receptor signaling pathway GO:0007166 9.8 NPPB IL2RA IFNB1 IFNA2 EGFR CXCL10
21 positive regulation of chemokine production GO:0032722 9.77 TLR4 IL6 ADAM17
22 positive regulation of interleukin-10 production GO:0032733 9.77 TLR4 IL6 IL4
23 lipopolysaccharide-mediated signaling pathway GO:0031663 9.76 TLR4 IL1B CCL2
24 positive regulation of interleukin-8 production GO:0032757 9.76 TLR4 IL6 IL1B F3
25 immune response GO:0006955 9.76 TLR4 IL6 IL4 IL2RA IL1B CXCL8
26 positive regulation of phosphorylation GO:0042327 9.75 NRP1 IFNA2 EGFR
27 humoral immune response GO:0006959 9.73 IL6 IFNB1 IFNA2 CCL2
28 regulation of blood vessel diameter GO:0097746 9.72 NPPB ACE2 ACE
29 positive regulation of MHC class II biosynthetic process GO:0045348 9.68 TLR4 IL4
30 positive regulation of leukocyte chemotaxis GO:0002690 9.67 IL6 CXCL10 ADAM17
31 negative regulation of T cell differentiation GO:0045581 9.64 IFNB1 IFNA2
32 vascular endothelial growth factor production GO:0010573 9.63 IL6 IL1B
33 regulation of systemic arterial blood pressure by renin-angiotensin GO:0003081 9.63 ACE2 ACE
34 negative regulation of T-helper 2 cell cytokine production GO:2000552 9.61 IFNB1 IFNA2
35 neutrophil mediated immunity GO:0002446 9.58 IL6 ADAM17 ACE
36 negative regulation of gap junction assembly GO:1903597 9.56 IL1B ACE
37 inflammatory response GO:0006954 9.56 TLR4 IL6 IL2RA IL1B IFNA2 CXCL8
38 cytokine-mediated signaling pathway GO:0019221 9.32 IL6 IL4 IL2RA IL1B IFNB1 IFNA2

Molecular functions related to Covid-19 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.26 TNNI3 TMPRSS2 TLR4 NRP1 NPPB IL6
2 virus receptor activity GO:0001618 9.61 EGFR DPP4 ACE2
3 chemokine activity GO:0008009 9.54 CXCL8 CXCL10 CCL2
4 signaling receptor binding GO:0005102 9.43 TLR4 NPPB EGFR DPP4 CXCL10 CCL2
5 interleukin-6 receptor binding GO:0005138 9.4 IL6 ADAM17
6 cytokine receptor binding GO:0005126 9.33 IL4 IFNB1 IFNA2
7 peptidyl-dipeptidase activity GO:0008241 9.32 ACE2 ACE
8 cytokine activity GO:0005125 9.23 IL6 IL4 IL1B IFNB1 IFNA2 CXCL8

Sources for Covid-19

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....